TY  - JOUR
AU  - Moya-Alarcón, Carlota
AU  - González-Domínguez, Almudena
AU  - Simon, Susana
AU  - Pérez-Román, Inés
AU  - González-Martín, Antonio
AU  - Bayo-Lozano, Eloisa
AU  - Sánchez-Heras, Ana Beatriz
PY  - 2019
DO  - 10.1007/s12094-018-02026-2
UR  - http://hdl.handle.net/10668/13388
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Germline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC). The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade...
LA  - en
KW  - BRCA1 gene
KW  - BRCA2 gene
KW  - Cancer screening test
KW  - Cost–utility analysis
KW  - Ovarian cancer
KW  - Quality-adjusted life years
KW  - Adult
KW  - BRCA1 Protein
KW  - BRCA2 Protein
KW  - Breast Neoplasms
KW  - Carcinoma, Ovarian Epithelial
KW  - Cost-Benefit Analysis
KW  - Female
KW  - Follow-Up Studies
KW  - Genetic Predisposition to Disease
KW  - Genetic Testing
KW  - Germ-Line Mutation
KW  - Health Care Costs
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Grading
KW  - Prognosis
KW  - Quality of Life
KW  - Quality-Adjusted Life Years
KW  - Spain
TI  - Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
TY  - research article
VL  - 21
ER  -